Open access for upper gastrointestinal (GI) endoscopy, over the years, has increased the volume of procedures in all endoscopy units because of convenience and ease of use for primary care physicians [1] . One drawback to such a service is over utilization. Using the Swiss criteria developed by the RAND/UCLA panel for appropriateness, Froelich et al. found that 46% of 1681 patients referred to the open access system for an esophagogastroduodenoscopy (EGD) had clear indications, but 39% did not [2] . Those patients who had clear indications were found to have pathology much more frequently than those who did not (60% vs. 37%; O.R. 2.6; 95% CI [2.2, 3.2]), confirming the notion that a high number of open access endoscopic procedures may be unnecessary [2] .
Another draw back to the open access system is the lack of proper informed consent. This was demonstrated in a study by Staff et al. who compared the extent of preprocedure information for patients referred by primary care physicians, through the open acces system, with that of patients referred by gastroenterologists, using a 1-page questionnaire [3] . The study found that not only did the patients referred through the open access system feel that they received less information than their counterparts (24% vs 15%, P < 0.01), they also felt that they were given less explanation about their respective procedures than their counterparts (38% vs 17%, P < 0.02).
Therefore, in this era of the open access system, it is crucial that proper patient selection is exercised and that proper patient consent is obtained to minimize over utilization and to maximize patient understanding of all endoscopic procedures, especially interventional ones.
Proper anticoagulation protocol
According to the American Society for Gastrointestinal Endoscopy (ASGE) guidelines, patients who are on anticoagulation therapy need to be categorized on two levels. The first level is based on their potential to embolize. The second level is based on their potential to bleed as a result of proposed endoscopic procedures. Based on these criteria, the only patients who are considered at high risk for embolization are those with mechanical valves and those with atrial fibrillation known to be associated with valvular heart disease. Patients considered at high risk for bleeding from their proposed endoscopic procedures are those who are about to have one of the following procedures: polypectomy, endoscopic retrograde pancreatography (ERCP) associated with a sphincterotomy, pneumatic dilatation, percutaneous endoscopic gastrostomy tube placement, laser ablation, variceal ablation therapy, and endoscopic ultrasoundguided fine needle aspiration. Only those patients at high risk for embolization, also considered at high risk for bleeding, would need to follow the full anticoagulation protocol before having an endoscopic procedure. This protocol would require in-hospital anticoagulation with a heparin drip (Table 1) . All other potential categories of patients can safely be treated with outpatient management protocols (Table 1) . No randomized trials have tested these recommendations. However, in a retrospective study by Gerson et al., these recommendations were evaluated without any apparent adverse outcome [4] . In fact, these recommendations seem to have produced a significant cost reduction of $74,000 over the study period. Therefore, adherence to these ASGE guidelines may provide a safe, cost-effective approach to manage anticoagulation in patients who are about to have endoscopic procedures.
Proper sedation
Patient comfort is crucial for the successful and safe performance of all endoscopic procedures, especially the interventional ones. Traditionally, this has been achieved through the use of a narcotic analgesic agent and a benzodiazepine. In patients with a history of narcotic use or heavy alcohol, use this approach may be ineffective. Two new agents have been evaluated over the past few years to help in the sedation of this group of patients. These include droperidol and propofol.
Droperidol
Droperidol (Inapsine, Janssen Pharmaceutica, Toronto, Ontario, Canada) is an intermediate-acting butyrophenone neuroleptic tranquilizer that can provide antianxiety effect and mild sedation in conjunction with narcotics and benzodiazepines, with excellent results in difficult to sedate patients. In a study of 100 randomized patients who had therapeutic endoscopy, the droperidol group had fewer procedure interruptions, and required less midazolam (23%) and less meperidine (16%) than the control group. Furthermore, no difference occurred in time to reach sedation or recovery room time between the two groups [5•]. Contraindications to its use are patients on phenothiazine, patients with history of seizures, or patients with history of Parkinson's disease.
Propofol
Propofol (Diprivan, Zeneca Pharmaceuticals, Wilmington, Delaware) is an intravenous sedative hypnotic that can be used to induce and maintain conscious sedation with excellent results in endoscopy. In a study by Koshy et al., 274 elderly patients with multiple comorbid conditions having GI endoscopy were randomized to propofol versus fentanyl and midazolam. The procedures were completed without difficulty in either group; however, patient comfort and shorter recovery time were noted in the propofol group [6] . Similar findings were reported in children [7] . However, propofol has been mostly limited to use by anesthesiologists because of the inadequacy of current endoscopic monitoring devices to detect early stages of respiratory depression. A recent trial by Zuccaro et al. tested the use of a specialized nasal cannula to detect carbon dioxide via infrared spectroscopy. Results indicate that this specialized cannula, which detects early signs of respiratory depression, allows the safe use of propofol by the endoscopist [8].
Therefore, through the use of these newer pharmacologic agents, proper patient sedation can be achieved, even in potentially difficult to sedate patients who have a history of narcotic use or heavy alcohol use.
Specific issues

Hemostasis
To implement therapy in patients with upper gastrointestinal (UGI) tract bleeding, two crucial points must be addressed: the need for urgent endoscopy and the need to identify the bleeding site. The need for urgent endoscopy in patients with UGI bleeding raises unique triage questions that do not need to be addressed by any other interventional procedure. For example, how soon does the patient need to be endoscoped? Is it safe to proceed in the setting of chest pain and a suspected myocardial infarction? Should intubation for airway protection be considered in this group of patients? (These triage issues are discussed in detail in the next section.) Technologies aimed at identifying and treating feeding vessels during endoscopy, to a large extent, have been "hit or miss.'' A number of techniques have been evaluated to identify the course of feeding vessels in patients with arterial bleeds. Unfortunately, for the most part, they have been largely unsuccessful. The only exception to this is that of Doppler ultrasound [19, 20] . Nevertheless, even Doppler ultrasound remains deficient in a number of significant ways that limit its clinical utility and therapeutic efficacy.
Technologies aimed at developing mechanical hemostasis to treat patients with UGI bleeding with an underlying coagulopathy (eg, banding and hemoclipping) have had a better outcome. In a prospective, randomized trial of patients with bleeding ulcers with major stigmata of bleeding, patients were randomized to hemoclipping versus heat therapy [21•]. Those who had hemoclipping had significantly less recurrent bleeding than those in the heat probe therapy group (1.8% vs 21%; P < 0.05), with a significantly reduced hospitalization and fewer transfusion requirements. This same technique has also been successful in the management of arterial bleeding from Dieulafoy lesions. In a prospective, randomized trial, patients with UGI bleeding caused by Dieulafoy lesions were randomized in a prospective fashion to mechanical therapy (nine hemoclips, three bands) versus injection therapy [22] . Initial hemostasis was superior in mechanical hemostasis (91.7% vs 75%), as was the incidence of recurrent bleeding (8.3% vs 33.3%; P < 0.05) and need for surgery (0% vs 17%).
Pharmacotherapy, when used appropriately, also reduces therapeutic failures in patients with bleeding peptic ulcers. For example, in patients who were Helicobacter pylori positive, eradication therapy was shown to prevent recurrent bleeding. In a study of 103 patients with H. pylori infection and bleeding duodenal ulcers, following endoscopic hemostasis, triple therapy, and eradication of the bacterium, as documented by urea breath test, the risk of rebleeding was decreased to 0.6% over a 27-months follow-up period [23] . Similarly, in patients who were H. pylori negative, the intravenous use of proton-pump inhibitors has decreased the rebleeding rate. In a prospective, randomized trial, patients with bleeding ulcers had endoscopic hemostasis [24•]. Subsequently, they were randomized to receive intravenous proton pump inhibitors (80 mg i.v. bolus, followed by 8 mg i.v. drip/hr for 72 hr) or placebo. Both groups were then placed on oral proton pump inhibitors for 8 weeks and monitored. Recurrent bleeding was significantly reduced from 27/120 (22.5%) in the placebo group to 8/120 (6.7%) in the therapeutic group. The reason for this benefit is not clear. However, it is postulated that proton pump inhibitors decrease gastric acidity, allowing for clots and healing to develop [25, 26] .
The benefits obtained from pharmacotherapy in both groups of patients seem to hold true even in patients who are on low dose aspirin or naproxen [27] . Therefore, hemostasis in patients with arterial bleeds can no longer be considered complete until mechanical hemostasis has been considered and proper pharmacotherapy has been administered.
Hemostasis: varices
In a review by Taso et al., the treatment of esophageal and gastric varices was discussed [28••]. The use of a nonselective beta-blocker aimed at decreasing the heart rate by 25% to prevent the first bleeding episode from gastric varices is well supported. To promote hemostasis in patients with actively bleeding gastric varices, sclerotherapy and banding were found to be disappointing [28] . Intravariceal thrombin injection, a newer modality, has recently emerged to treat this group of patients with a better outcome [29] . In an open-labeled trial, thrombin was found to induce initial hemostasis in 49/52 (94%) patients with bleeding gastric varices, with a low rebleeding rate (6%) at 72 hours, and a low mortality rate (16%) at 6 weeks [30] . Unfortunately, these benefits seem to be limited to patients with localized gastric varices. Patients with diffuse-type gastric varices seem to have a significantly higher rebleeding rate (6/37 vs 0/14; P < 0.0001), lower eradication rate (21/37 vs 12/14; P < 0.001), and higher complication rate (7/37 vs 0/14; P < 0.05) when treated with intravariceal thrombin injection, compared with their counterparts with localizedtype disease [31] . The reason for this discrepancy is not clear but may be related to leakage of the material into the bloodstream. In a case report of a patient with diffuse-type bleeding gastric varices, autopsy revealed that intravariceal injection of large volumes of thrombin leaked into the blood stream, inducing systemic thrombosis and death [32] . Unfortunately, thrombin is not yet widely available for use in the United States, and treatment of bleeding gastric varices still largely focuses on endoscopic sclerotherapy and banding with suboptimal results. Failed cases are referred to surgery for portosystemic shunt surgery, if Child's class A, and to radiology for transjugular intrahepatic portosystemic shunts (TIPS) if Child's class B or greater.
Following endoscopic therapy, recurrent bleeding has been reduced in patients with esophageal varices treated with octreotide [33]. This action seems to be mediated through local vasoconstriction of vascular smooth muscles via endothelin (ET-1) [34] . Octreotide use can also be helpful in decreasing the rate of recurrent bleeding from gastric varices following endoscopic therapy.
Assuming that vasoconstriction would be as helpful in decreasing rebleeding from gastric varices as it would from esophageal varices, use of octreotide can easily be justified-even in this group of patients-until more data are available.
Hemostasis: vascular ectasias
Although a number of modalities can be used to treat diffuse antral vascular ectasia (DAVE), argon plasma coagulation (APC) seems to be the most effective and safest technique [35] . APC is a noncontact, diathermybased technique where the argon gas is passed through a coagulation probe with an electrode at its tip. Once the electrode is activated by a foot switch, current passes through the argon cloud ionizing it and enabling it to conduct a spark to the nearest point of contact with tissue, resulting in hemostasis.
In vitro studies have demonstrated that the argon plasma coagulation technique is self-limited, causing ablation of the superficial layers of the stomach only [35] . Using freshly isolated esophageal and gastric tissues, APC probes were placed at a 90-degree angle from the specimen, with a 1-mm separation; activated at a power setting of 4 to 90 W with pulses lasting 1 to 3 seconds. Diathermy was found to extend into the muscularis propria in 1/42 of the esophageal specimens and 3/42 of the gastric specimens [35] . More tissue damage occurred at higher pulse duration, although the damage still did not extend through the entire wall thickness. Although it is difficult to extrapolate in vitro studies to in vivo guidelines, this study indicates that APC may be a safe and effective technique to ablate superficial bleeding gastric vessels at low pulse durations at power settings less than 90 W. Case reports indicate that monopolar electrocoagulation with polidocanol injection and endoscopic laser is another useful technique to use in the management of the DAVE syndrome [36, 37] . However, limited available data support these latter techniques.
Hemostasis: disposition
Following hemostasis, the disposition of patients with UGI bleeding is not always clear. To identify patients at high risk who need intensive care unit (ICU) monitoring, a number of systems have been developed over the years, including the Baylor and the Rockall scores [10].
An easier system was recently developed identifying a number of clinical and endoscopic parameters in patients admitted with acute UGI bleeding, following the patients' courses, and using logistic regression analysis to identify clinical and endoscopic criteria that were predictors of poor outcome (rebleeding rate, emergency surgery, or death) [38] . According to this system, only four factors were found to be predictive of poor outcome. These included high Acute Physiology and Chronic Health Evaluation (APACHE) II scores, active bleeding at the time of presentation, end-organ dysfunction, and the presence of hepatic cirrhosis. Although intriguing, the study and the system suffer from a number of deficits. It was a small study at a single institution. It did not include other factors (age and hypotension) usually thought to be predictive of poor outcome in patients with UGI bleeding. Therefore, although the score is an easier system to use, it warrants further evaluation and validation before widespread use can be recommended.
Endoscopic ultrasound
Endoscopic ultrasound (EUS) is a useful technique that permits the detailed evaluation of the gastrointestinal tract wall [39] . This evaluation can be applied in three clinical situations (a) gastric cancer staging,(b) thickened gastric fold evaluation, and (c) flexible endoscopic surgical procedures guidance through the stomach wall.
Gastric cancer staging is crucial in the treatment algorithm of the disease. Patients with early disease can be treated with minimally invasive techniques (eg, endoscopic mucosal resection or photodynamic laser therapy), whereas those with advanced disease need to be treated aggressively with surgery in conjunction with adjuvant chemoradiotherapy. EUS is currently the best modality available to differentiate between early and locally advanced disease (Fig. 1) . Studies have demonstrated overall staging accuracy rates of 78% to 96% (Table 2) [40,41,42]. However, the technique is not error-free.
Overstaging has been described in cases of inflammation adjacent to tumor and understaging has been demonstrated in cases of microinvasive cancer [40] .
Thickened gastric fold evaluation can be challenging. lesions (cysts, extrinsic masses and lipomas), problems in interpretation can arise because of operator inexperience [45] . When these diagnostic dilemmas arise and the presence of varices has been excluded by EUS, tissue acquisition by endoscopic mucosal resection is one way to resolve them.
Flexible endoscopic surgical procedure guidance, through the stomach wall, is another potential future application for EUS. This technique can be applied in forming hepaticogastrostomies or gastrojejunostomies to bypass obstructed areas in patients with pancreatic cancer. These techniques have been successfully demonstrated in the animal model, but still await human trials [46,47,48].
Endoscopic mucosal resection
With increased surveillance, a rise is seen in the reported incidence of premalignant and early malignant lesions in the stomach. These lesions can be treated surgically, endoscopically through ablation therapy, or endoscopically through a newer technique referred to as endoscopic mucosal resection (EMR). EMR is a technique that relies on submucosal injection (saline, epinephrine, or a combination) to separate the mucosa from the muscularis propria followed by their en toto resection by the snare or the suction cap technique (Fig. 2) [49]. The technique is less invasive than surgery, but seems to be equally effica-cious in cases of early gastric cancer. Published series have demonstrated recurrence-free survival for up to 5 years in 86% to 98% of the patients (Table 3) [41,50,51,52]. To identify selection criteria for good outcome, Miyata et al. retrospectively evaluated 251 patients who had EMR [53] . He found three criteria to be of paramount importance: (a) size of lesion (<15 mm), (b) histologic type (well-differentiated), and (c) level of cancer involvement (intramucosal). When these criteria were used, the technique was performed successfully and safely. Therefore, in properly selected patients, EMR seems to be gaining acceptance as a viable minimally invasive technique for the safe treatment of premalignant and early malignant lesions of the stomach.
Enteric stenting
Malignant obstruction of the stomach or duodenum is associated with progressive deterioration of a patient's quality of life as a result of nausea, vomiting, and malnutrition [54] . This problem can be addressed in a number of ways: dilatation, heat ablation therapy, and stenting [54] . Of these, stenting seems to be the most successful. 
Stents come in a variety
Figure 2.
Schematic of endoscopic mucosal resection (EMR) demonstrating the use of the "suction cap'' technique. 2. Injection of contrast material to identify the lesion and measure its length, 3. Exchange of the catheter to a stiff guidewire (±dilatation) 4. Placement and deployment of the stent In the largest trial to date, 29/31 (93.5%) of the patients with malignant gastroduodenal obstruction had successful stent placement [58] . Of these, good clinical outcome was achieved in 25/31 (80.6%) with reobstruction by tumor in-growth developing in 2 patients at a mean follow-up of 183 days. Furthermore, it may provide a less invasive alternative to palliative surgical gastrojejunostomies. When compared with a similar group of patients who had surgical gastrojejunostomies for decompression, patients with stent placement had the same length of survival (94 days vs 92 days) at a reduced cost ($9,921 vs $28,173; P < 0.005) and shorter hospitalization (4 days vs 14 days; P < 0.005) [58] . Complications included distal obstruction (5%), tumor obstruction (15%), and stent migration (3%). These results have been reproduced in a smaller series where the success of stent placement occurred in 18/19 patients, with symptomatic relief in 17/19 [59] . Therefore, enteric stenting is now a safe, less-invasive alternative to surgery that can be used in the palliation of patients with gastroduodenal malignant obstruction.
Percutaneous endoscopic gastrostomy Indications
Percutaneous endoscopic gastrostomy (PEG) tube placement is a therapeutic technique used to provide nutritional support to patients with poor oral intake because of cerebral vascular accidents, head injury, head and neck cancer, or nasopharyngeal dysphagia. At times, it has been used to provide nutritional support in a number of other conditions (eg, human immunodeficiency virus and dementia). Recent studies, however, indicate that its use in dementia may be detrimental to the patients. Sanders et al. demonstrated that, whereas the post-PEG 30-day mortality in patients who are not demented is 28%, it reaches 54% in those with dementia and rises to 90% at 1-year [60] . Therefore, although PEG placement is a safe and widely available technique, it should not be used in all patients. Careful patient selection remains crucial.
Percutaneous endoscopic gastrostomy: timing
Timing is another important consideration in PEG placement. In a retrospective review of patients with head and neck cancer, Lee et al. found that early prophylactic placement of the PEG in this group of patients was beneficial [61] . Patients with prophylactic PEG placement had less weight loss (3.1 kg vs 7.0 kg; P < 0.001), reduced hospitalizations for malnutrition (13% vs 34%; P = 0.04), and fewer treatment interruptions (0% vs 18%; P = 0.08) than those whose PEG was placed following the devel-opment of signs and symptoms of malnutrition [61] . Therefore, in selected cases, when the need for PEG placement is inevitable, early placement may be beneficial for the patient.
Role of speech therapy
PEG placement is only one component of therapy for malnutrition. In appropriate patients, the inclusion of other components (eg, speech therapy) may be of benefit to the patient. In a study by Klor and Milianti, 36 patients with oropharyngeal dysphagia were evaluated and found to be appropriate candidates for speech therapy [62] . Following the induction of speech therapy, 16/36 patients had improvement in their oral intake sufficient to permit the removal of their PEGs at 6 months, resulting in improvement in their quality of life and significant cost savings. Therefore, it is important to remember that PEG placement is a temporary measure of nutritional support; the judicious use of other components of therapy (eg, speech therapy) in selected patients may allow its early removal and lead to improved outcomes and significant cost savings.
Photodynamic laser therapy
Photodynamic laser therapy (PDT) is a procedure initially introduced for the treatment of esophageal cancer and Barrett's esophagus [63] . Recently, its use has been applied to gastric cancer [63] . It relies on three components: a photosensitizer (Photofrin II, Axcan Pharma, Montreal, Canada), laser light, and oxygen [64] . The photosensitizer is administered intravenously and taken up by abnormal tissues. Within 24 to 48 hours, it reaches maximal concentration in those tissues. The application of photoradiation to these tissues through laser light, in the presence of oxygen, activates the photosensitizer, resulting in tissue destruction. Optimal dosage for gastric cancer therapy is 2 mg/kg of Photofrin II with a power setting of 30 to 50 J/cm 2 [64] .
Using this regimen, Ell et al. demonstrated complete remission in 6/22 (73%) patients with early gastric cancer during a follow-up period of 20 months [65] . No severe complications were reported. However, 7 patients developed mild photosensitivity reactions that responded to conservative therapy. Although further study is indicated, early data would seem to indicate that PDT provides another nonsurgical alternative for early gastric cancer therapy.
Future issues
Clearly, tremendous developments have occurred over the years in the area of interventional gastric endoscopy. Yet, more developments seem to be on the horizon in terms of improved image acquisition, patient comfort, and accessories that allow the performance of more invasive procedures.
Image acquisition
To improve image acquisition technology, a number of new technologies are under active investigation. These include optical coherence tomography (OCT), autofluorescence endoscopy, and near infrared electronic endoscopy [66, 67, 68, 69] . Of these technologies, the most promising seems to be that of OCT. This imaging technique produces high-resolution cross-sectional images of tissue in vivo. It is analogous to ultrasonographic imaging but with a much higher image resolution capacity. It is performed by placing a probe into the instrument channel of a diagnostic endoscope. In vivo endoscopic coherence tomography of the GI tract provides such detailed images of the mucosal that it has been labeled an "instrument of optical biopsy'' [70, 71] . It has a reported sensitivity of 100% and specificity of 93% when used to identify intestinal metaplasia in the distal esophagus [72] .
Patient comfort
To improve patient comfort during procedures, a number of modifications of current technology are being evaluated. These include the ultrathin endoscopes and wireless endoscopy.
The ultrathin endoscopes are instruments available (Olympus America, Melville, NY; and Pentax Corp., Orangeburg, NY) that have a tube diameter of 5.3 to 6 mm. They allow tip movements similar to conventional endoscopes with working channels of 2 mm [73] . Their major advantage is the performance of nonsedated diagnostic EGD. Using ultrathin endoscopy without sedation, Sorbi et al. could identify 97% of the pathology that was subsequently confirmed by sedated conventional endoscopy, in 40 patients [74] . The only missed finding was that of a gastric varix, which was misinterpreted as a thickened fold. An increase was seen in the incidence of choking (3.7 vs 1.8; P < 0.0005) over that of sedated conventional endoscopy. Nevertheless, 98% of the patients were satisfied and willing to have the procedure repeated in the same fashion.
Wireless endoscopy, a newly developed technique [75] , relies on swallowing a capsule that contains a miniaturized endoscope containing a complementary metal oxide silicon (CMOS) chip camera, transmitter, light-emitting diode (LED) illumination, and silver oxide batteries (Fig. 3) . It has no wires, external cables, or optical fibers. The image is transmitted to a hard drive recorder worn on the patient's belt. Once the examination is completed, the data are downloaded to a computer workstation and reviewed. In an animal trial, it outperformed enteroscopy with a sensitivity of 64% vs 37% and a specificity of 97% vs 92%, easily passing out of the GI tract without any difficulty [76•]. In the only human trial to date, it was comparable to enteroscopy, able to identify pathology in 7/11 patients [77]. However, it outper-formed enteroscopy by finding lesions in 5/9 patients that were distal to the reach of the enteroscope. Clearly, more work is needed with this new technology. In fact, a multinational trial is currently underway. Nevertheless, if these early findings are borne out, wireless endoscopy would add to the diagnostic armamentarium of the gastroenterologist, allowing visualization of areas in the small bowel not previously seen.
Accessories of the future
To allow for more invasive endoscopic procedures, new accessories are being developed. One such example is an endoscopic device that allows mucosal approximation of tissues to repair perforations. Case reports, for example, have demonstrated the successful application of hemoclips to close gastric perforation [78] . In time, some of the distinction between surgical and endoscopic procedures will diminish if the technologic developments in the field and in the accessories available for use continue to progress at the same pace as they have over the past 20 years. 
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